Page 48

No. 154

Authors :

Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, Sirachainan E, Maoleekoonpairoj S,

Phromratanapongse P, Cheirsilpa A, Tangkaratt S, Srimuninnimit V, Pattaranutaporn P,

Lertsanguansinchai P.

Title :

Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung

cancer (NSCLC): a preliminary report.

Source :

Journal of the Medical Association of Thailand. 83(1):85-92, 2000(Jan).

Keywords :

Bulky, Non-small cell lung, Cancer, NSCLC

Abstract :

We designed a phase II study to determine the feasibility and toxicity of concomitant radiotherapy and

Paclitaxel/Carboplatin followed by adjuvant chemotherapy of the same regimen in patients with newly

diagnosed inoperable stage III A/B non-small cell lung cancer. Patients were irradiated with a total dose of

66 Gy. Weekly courses of Paclitaxel 45 mg/m2 and Carboplatin AUC 2 were administered intravenously

during the irradiation period. After completion of concurrent chemoradiotherapy, adjuvant chemotherapy

with Paclitaxel 175 mg/m2 and Carboplatin AUC 6 intravenously every 3 weeks for 4 cycles were given.

Since March 1998, 15 patients have been enrolled. All patients were assessable for efficacy and toxicity

after concurrent chemoradiotherapy. Eleven patients were assessable for efficacy and toxicity after adjuvant

chemotherapy. After concomitant chemoradiotherapy, complete response (CR) was documented in 2 of 15

(13%). Partial response (PR) was documented in 9 of 15 (60%). After completion of adjuvant chemo-

therapy in 11 patients, the overall response rate was 91 per cent. (18% CR, 73% PR). There were 8 per cent

gr. 3-4 neutropenia which occurred during adjuvant chemotherapy. Concomitant Paclitaxel/Carboplatin and

radiotherapy are promising modalities in the treatment of inoperable stage III A/B non-small cell lung cancer.

No. 155

Authors :

Ratanatharathorn V, Sirachainan E, Jirajarus M, Sirilerttrakul S.

Title :

Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-

treated with fluorouracil-based chemotherapy.

Source :

Journal of the Medical Association of Thailand. 83(10):1187-95, 2000(Oct).

Keywords :

Metastatic colorectal carcinoma, Fluorouracil-based chemotherapy, CRC

Abstract :

The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan

(CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC). Sixteen patients with

World Health Organization (WHO) performance status < or = 2 were treated with CPT-11 350 mg/m2 every

3 weeks. The observed partial response (PR) rate was 6.3 per cent with a high rate of stable disease (SD)

(43.7%) which was of long duration (21.1 weeks for the best response; 1PR, 7SD). The median survival time

for the 16 patients entered into this study was 69.6 weeks. There was no toxic death. The most frequent

adverse events were neutropenia (31% grade 3/4) and delayed diarrhea (9.7%). CPT-11 has definite activity

in the treatment of progressive metastatic CRC truly resistant to 5-FU which translated into clinical survival

benefit. Median survival from first administration of CPT-11 was 78.6 weeks for patients with best response

(PR + SD) compared with 28.1 weeks for patients with progressive disease (PD) (P = 0.01). With the

appearance of new active drugs in this highly chemotherapy-resistant disease, the definition of response

should be reassessed in CRC.

No. 156

Authors :

Ratanatharathorn V, Sirachainan E, Jirajarus M.

Title :

Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell

lung cancer.

Source :

Journal of the Medical Association of Thailand. 83(9):1059-67, 2000(Sep).

Keywords :

Non-small-cell, Lung cancer, Quality of life, NSCLC, Quality of Life Index

Abstract :

The purpose of this phase II study was to determine the effects of paclitaxel plus carboplatin administered

by short duratio n on response rate, toxicity, and quality of life (QOL) in patients with non-small cell lung

cancer (NSCLC). Twenty-seven patients were enrolled in this study. The objective response rate was 48.2 per

cent, grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 22 per cent and 1.6 per cent,

respectively. QOL was assessed in nineteen patients who completed six cycles of chemotherapy. Quality

of Life Index (QLI) after six cycles of treatment showed no significant change from the baseline QOL.

Compliance with the QOL protocol in this study diminished with the course of chemotherapy which is

comparable to the literature figure. Thus, withholding current effective chemotherapy in patients with

NSCLC with good performance status is no longer justified.

No. 157

Authors :

Rerkamnuaychoke B, Chantratita W, Jomsawat U, Thanakitgosate J, Pattanasak N, Rojanasunan P.

Title :

Comparison of DNA extraction from blood stain and decomposed muscle in STR polymorphism analysis.

Source :

Journal of the Medical Association of Thailand. 83(Suppl 1):S82-8, 2000(Mar).

Keywords :

DNA, STR polymorphism analysis, PCR-based STR polymorphism analysis

Abstract :

Forensic samples that are often degraded and limited in quality cause DNA typing analysis by conventional

methods unsuitable. We performed a single tube-multiplex PCR on 9 STR loci (D3S1358, vWA, FGA, TH01,